Table 3.
Study Population | Assay | AUC | Sensitivity | Specificity | Optimal Cut-Off Value (pg/mL) | |
---|---|---|---|---|---|---|
Xue et al. [36] | 111 cognitively-normal controls, 193 MCI, 95 AD | Electrochemiluminescence technology using Ng7 |
0.71 | NA | NA | NA |
Fan et al. [37] | 65 cognitively-normal controls, 65 AD | Electrochemiluminescence technology using Ng7 |
0.783 | NA | NA | NA |
Galasko et al. [38] | 90 normal controls, 46 AD | ELISA (EUROIMMUN, Lübeck, Germany) | 0.504 | 0.200 (0.022–0.311) |
0.854 (0.640–0.932) |
167.78 |
Schipke et al. [39] | 20 MDD, 20 AD | In-house ELISA | 0.696 | NA | NA | NA |
Mattsson et al. [40] | 93 controls, 93 AD | In-house ELISA | 0.85 | NA | NA | 254.7 |
Tarawneh et al. [41] | 207 controls, 95 AD | 2-site immunoassay uses an affinity-efficient trapping and purification technique for polyclonal antibodies | 0.71 | NA | NA | NA |
Janelidze et al. [42] | 74 AD | In-house ELISA | 0.761 | NA | NA | NA |
MCI, mild cognitive impairment; AD, Alzheimer’s disease; NA, not available; ELISA, enzyme-linked immunosorbent assay; MDD, major depressive disorder.